TRT and Blood Pressure — Can Testosterone Therapy Raise It?

When men read about the side effects of testosterone replacement therapy, attention usually centers on hematocrit, PSA, fertility, or acne. Blood pressure less often makes the top of the list — which is a shame, because it's one of the few parameters that randomized trials actually show differs between the testosterone-treated group and placebo, and one you can measure with an ordinary cuff in a doctor's office, without waiting for lab results.

The answer to the question in the title isn't a simple "yes" or "no," though. The literature on TRT and blood pressure is mixed — some studies show a small but statistically significant rise, others show no difference from placebo at all, and still others suggest the effect appears mainly in men whose therapy noticeably raised hematocrit. This article sorts through that picture: what's specifically known, what mechanism explains it, who it affects most, and how to sensibly monitor blood pressure during therapy — treating it neither as a reason to panic nor as a topic that can be skipped.

Large meta-analyses of placebo-controlled randomized trials assessing TRT's overall cardiovascular safety usually find no significant difference in the rate of major cardiovascular events (heart attack, stroke, cardiovascular death) between the treated group and placebo — a well-documented, reassuring result, confirmed among others in the TRAVERSE trial, the largest randomized study to date assessing testosterone's cardiovascular safety in men with hypogonadism and elevated cardiac risk. Blood pressure as a single, isolated parameter, though, is a somewhat different story — here individual study results diverge depending on the population, delivery form, follow-up length, and how blood pressure was measured (a single office reading versus 24-hour ambulatory blood pressure monitoring, ABPM).

Some observational and shorter-term randomized studies show no significant change in average blood pressure with TRT in a typical, well-selected hypogonadal patient. Others, especially those using more precise 24-hour monitoring instead of a single office reading, pick up a small but statistically significant rise — most often on the order of a few millimeters of mercury in systolic pressure. This discrepancy is partly explained by the effect not being uniform across the treated population — it appears more pronounced in men whose therapy significantly raised hematocrit, and in others it's practically undetectable.

The best-documented pathway through which TRT can raise blood pressure isn't a direct effect of testosterone on blood vessels, but an indirect one — via a rise in hematocrit, the percentage of red blood cells in blood volume. Testosterone is one of the strongest physiological stimulators of erythropoiesis, and in some treated men — especially with injectable forms that generate high peak concentrations — this leads to secondary erythrocytosis. Denser, more viscous blood offers greater resistance to flow in peripheral vessels, which translates into higher pressure needed to pump it through the circulatory system. This is a purely physical (rheological) phenomenon, not a hormonal one in the narrow sense — analogous to why people with polycythemia vera or chronic hypoxia (e.g. high-altitude residents, heavy smokers) more often have elevated blood pressure.

The practical consequence is simple: men in whom TRT noticeably raises hematocrit — more often those on injectable testosterone forms given infrequently at large doses — are also the group in which a measurable blood pressure rise is most likely. That's an additional argument for treating hematocrit monitoring and blood pressure monitoring as two parts of the same, coherent therapy-safety picture, rather than two separate, independent topics.

Alongside the hematocrit-related effect, the literature also describes a smaller, more direct mechanism: testosterone can, in some men, increase sodium and water retention by the kidneys, partly through effects on the renin-angiotensin-aldosterone system and interactions with mineralocorticoid receptors. This effect is usually more modest than the hematocrit-mediated one and varies more between individuals — in some patients it shows up as subtle ankle swelling or a feeling of "puffiness" in the first few weeks of therapy, which itself can be a sign of fluid retention worth noting alongside a blood pressure check.

The TRAVERSE trial, published in the New England Journal of Medicine, remains the most important source to date of data on TRT's overall cardiovascular safety — testosterone didn't significantly increase the risk of major cardiovascular events (MACE) versus placebo in men with hypogonadism and elevated cardiac risk, though more cases of atrial fibrillation, acute kidney injury, and pulmonary embolism were noted in the treated group. Later, supplementary analyses of ambulatory blood pressure monitoring (ABPM) conducted within the same research program on testosterone safety found that testosterone products can raise blood pressure to a degree sufficient to warrant an update to product labeling — one reason some testosterone product labels today carry a blood pressure warning.

TRT's effect on blood pressure isn't spread evenly across the treated population. Several groups appear particularly prone to a measurable rise, which is worth factoring in at the qualification stage and when planning follow-up frequency.

Blood pressure doesn't require a separate, complicated monitoring protocol during TRT — it's enough to treat it as a standing part of the same follow-up visit where blood count, lipid panel, and PSA are assessed. In practice this means measuring blood pressure at every doctor's visit tied to therapy, not just the first qualifying visit.

Blood pressure should be assessed already at the qualification stage for therapy, not only after starting it — it's one element of the broader, standard cardiovascular risk assessment preceding TRT, which also includes a blood count with hematocrit, a lipid panel, and a history of cardiovascular disease. A man with untreated or poorly controlled hypertension isn't automatically disqualified from TRT, but sound clinical practice is to bring blood pressure under control — through lifestyle change, medication, or both — before or alongside starting testosterone therapy, so as not to start with two overlapping, uncontrolled variables at once.

The full scope of tests and assessments recommended before starting testosterone therapy — not just around blood pressure, but the overall qualification — is covered in detail in a separate post on pre-TRT testing. General guidance on managing hypertension itself, regardless of the testosterone therapy context, is covered in our dedicated post on hypertension.

For the large majority of men — with normal or well-controlled baseline blood pressure and no tendency toward an excessive hematocrit rise — the documented effect of TRT on blood pressure is modest enough that it isn't, by itself, a reason to forgo therapy for genuine clinical indications (confirmed hypogonadism with accompanying symptoms). It's really just another parameter that fits the same pattern as hematocrit, lipid panel, or PSA — something worth knowing, monitoring, and actively correcting if needed, rather than ignoring or letting discourage you from starting treatment in the first place.